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Background: SPIEDw is a web tool designed to facilitate fast and simple quantitative querying of publically
available gene expression data. The resource is motivated by the observation that transcriptional profiles can serve
as effective means of comparing biological states across a wide set of experiments.
Results: Gene expression data for over 200,000 experiments across multiple species and platforms have been
collected into a searchable database. The new resource is a development of the previously published SPIED, which
was designed to be downloaded and queried locally with SPIED software. SPIEDw features three significant
improvements over the original version. Firstly, the number of experiments covered has been doubled and now
includes Agilent and Illumina technologies. Secondly, SPIEDw has an enhanced search algorithm for speedy
web-based querying and lastly an abridged dataset comprising the most regulated genes has been included for a
speedier search and searching for enrichment of gene sets.
Conclusions: SPIEDw is simple to use, not requiring any expertise in microarray analysis, and the output
straightforward to interpret. It is hoped that this will open up gene expression data mining to the wider research
community.
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Gene expression data provides the most extensive quanti-
tative insight into biological processes with close to a mil-
lion separate data sets available [1,2]. The data is usually
analysed from a gene centric point of view, with the
objective of pinpointing a few perturbed genes that are
subsequently independently validated. Alternatively, ex-
pression profiles can be viewed as the regulation of prede-
fined gene sets representing canonical pathways [3] and
ontology classes [4,5]. Various web tools allow for the
navigation of deposited expression data. BioGPS [6] and
SOURCE [7] are tools for gene comparison based on cor-
relating expression profiles over large datasets. ArrayEx-
press Gene Expression Atlas [8] has compiled a database
of significantly changing genes across nearly 100,000 ex-
pression samples and the user can search for expression
series where a query gene or gene set are regulated. How-
ever, the observation that similar biological processes
often exhibit correlated gene expression changes hasCorrespondence: gareth.2.williams@kcl.ac.uk
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reproduction in any medium, provided the oropened up the possibility of using expression databases to
compare and contrast these processes [9,10]. In particular,
the connectivity map (CMAP) has made available expres-
sion data for over a thousand drug treatments of human
cell lines with the objective of mapping drug to disease
through direct expression profile correlation [11]. This
methodology has been extended to collections of pub-
lished expression studies in GEM-TREND [12], Profile-
Chaser [13], Gene Expression Atlas [8] and SPIED [14].
The motivation behind SPIED was in the first place to
define expression changes as relative to the average across
the experimental series and thereby facilitate automatic
curation and secondly to map expression changes to a
uniquely defined set of genes thus allowing for the data-
base to combine data from multiple platforms. The ori-
ginal version of SPIED has to be downloaded and searches
performed locally with SPIED software. Here we present a
web tool version of SPIED (SPIEDw). SPIEDw features a
speedier search algorithm enabling ‘real-time’ web-based
searching and consists of a greatly extended set of samples
covering human, mouse and rat species from Illumina,
Agilent and Affymetrix platform technologies, comprisingThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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exhaustive querying of global gene expression changes, a
speedier search can be made of an abridged database com-
prising the most regulated genes. This latter functionality
can also be deployed for gene set enrichment analysis.
Results
SPIEDw is hosted at www.spied.org.uk. Query expression
profiles consist of text files with the first two columns
corresponding to genes and their respective expression
values. Gene names are according to the HGNC (HUGO
Gene Nomenclature Committee) human gene nomencla-
ture, see www.genenames.org. Given that the overwhelm-
ing majority of gene names are identical across human,
mouse and rat queries can be constructed directly from
rodent array data files. Queries should not contain mul-
tiple instances of genes. When a query is input containing
multiple instances of a given gene only the first instance is
retained in the query. Therefore, if the query is ranked ac-
cording to significance only the most significant instances
will form the query. Expression values can be defined in a
number of ways, but treat up and down regulation symmet-
rically. Possible definitions are:
þ1 t > c
−1 t < c
, log tc
 
, t−ctþc ,Figure 1 A SPIEDw worked example. The SPIEDw web page screen shot
profile is uploaded, the user chooses whether to perform an exhaustive sea
genes. The latter is the appropriate option for performing gene list enrichm
number of top scoring samples returned can be increased beyond the def
corresponding to EGFR blockage in mouse neural stem cells [15]. The resul
correlation score and significance. The ‘magnifying glass’ button enables th
given series, displayed in the results column on the right. For example, the
inhibition in mouse mammary carcinoma cells [16], and as expected, this c
with the control samples.where t is the treatment and c the control values. The
database can either be queried exhaustively against the
global gene changes or against subsets of top up and down
regulated genes. Querying the latter database has the ad-
vantage of being much faster and unlike the global gene
expression database it can be meaningfully queried with
gene lists alone where it is of interest to look for enrich-
ment for up or down regulation across experiments in
SPIEDw. Searches can be restricted to a particular species
(Human, Rodent, Mouse, Rat) or performed against the
CMAP drug dataset. The output is in the form of a list of
series names, sample names and corresponding scores.
The output lists the top scoring samples and only one
sample per series. The series and sample entries link
to the relevant NCBI GEO (www.ncbi.nlm.nih.gov/geo/)
pages giving full descriptions of the experimental set up.
To see how the query scores against the whole series,
from which a high scoring sample originates, there is a
‘magnifying glass’ button link against each output sample.
The query scores against each sample in the series are
ordered according to correlation score and the associated
descriptors are shown. This is a simple way to see a pos-
sible correspondence between the biology underlying the
series and that of the query. For clarity, the SPIEDw webshowing the various controls in the left column. A gene expression
rch or search only an abridged dataset comprising the most regulated
ent queries. Searches can be restricted to specific species and the
ault 100. We have performed a full search of SPIEDw with a profile
ts column at the left lists the series id and sample id together with the
e user to see how the query scores against all the samples in the
EGFR antagonism profile scores highly against a study of PI3K/AKT
orrelation is positive with the inhibitor treated samples and negative
Table 2 Parkinson’s disease query correlates with the
expression profiles of multiple neurodegenerative
expression
Frontal temporal lobe dementia
Rank Series r Description
2 GSE13162 0.92 Samples with and without FTLD-U
Huntington’s disease
Rank Series r Description
5 GSE3790 0.84 Cerebellum, frontal cortex and caudate
nucleus HD tissue
Down’s syndrome
Rank Series r Description
7 GSE5390 0.84 Down syndrome and healthy control
subjects
86 GSE1397 0.55 Trisomy 21 and TS13
Bipolar disorder
Rank Series r Description
10 GSE5388 0.83 Adult dorsolateral prefrontal cortex: bipolar
disorder and healthy controls
11 GSE5389 0.83 Adult orbitofrontal cortex: bipolar disorder
and healthy controls
15 GSE5392 0.82 Adult brain tissue from subjects with bipolar
disorder and healthy controls
Alzheimer’s disease
Rank Series r Description
14 GSE16759 −0.82 Parietal lobe cortex in Alzheimer’s disease
26 GSE1297 −0.75 Incipient Alzheimer’s Disease
38 GSE5281 0.69 Alzheimer’s disease and the normal
aged brain
56 GSE12685 −0.63 Incipient AD
68 GSE4757 0.61 Alzheimer’s disease neurofibrillary tangles
Nasu-Hakola disease
Rank Series r Description
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example. With the current server configuration full sear-
ches take just over four minutes.
Examples of the use of SPIED in diverse disease con-
texts were presented in some detail in the original publi-
cation [14]. However, for completeness we present an
example where SPIEDw can be used to validate transcrip-
tional signatures from Parkinson’s (PD) disease and shed
light on animal models of PD. This complements the ana-
lysis of Alzheimer’s disease (AD) presented in [14]. The
notorious difficulty of obtaining good quality RNA from
post-mortem brain samples [17,18] raises legitimate con-
cerns over the robustness of neurodegenerative disease
associated transcription signatures. However, when there
is a significant correlation with independently derived
disease profiles in the public domain we can be more
confident that these profiles describe the disease. SPIEDw
offers a straightforward application here. To this end we
took a PD signature form a multi-regional brain expres-
sion study [19]. By combining the gene change profiles
form the three regions we defined a profile of 235 genes
(67 up and 168 down, see Additional file 1 for details).
When this profile is queried against the human subset of
SPIEDw we find nine independent PD profiles in the top
100 experimental series, see Table 1. Thus these results go
some way towards validating the profile. Profiles from
other neurodegenerative conditions also score highly, see
Table 2. Because the given expression series consists of
samples from multiple brain areas with corresponding
controls, a better idea of the disease correlation can be
seen between statistically filtered expression profiles based
on grouping control and disease sets. Example regression
plots are shown in Figure 2A and B and it is clear that
there is a substantial overlap between the PD query and
two independent PD profiles. This correlation is also seenTable 1 The PD query profile scores highly against nine
other PD expression studies, thus validating the query as
a disease signature
Parkinson’s disease
Rank Series r Description
1 GSE8397 −0.92 Parkinsonian Brain
3 GSE20168 −0.88 Prefrontal area 9 in Parkinson’s disease
13 GSE7621 −0.82 Substantia nigra from postmortem human
brain of Parkinson’s disease
21 GSE28894 −0.78 Multiple regions of the Parkinson’s
disease brain
58 GSE20141 −0.62 Laser-dissected SNpc neurons in
Parkinson’s disease
71 GSE4550 0.6 MPTP-treated macaques
89 GSE20292 −0.55 Substantia nigra in Parkinson’s disease
97 GSE19587 −0.53 Parkinson’s disease
99 GSE20291 −0.51 Putamen in Parkinson’s disease
33 GSE25496 0.73 Nasu-Hakola disease brain
Multiple sclerosis
Rank Series r Description
40 GSE5839 0.69 Multiple Sclerosis Brain tissue in comparison
to control brain tissue
Amyotropic lateral sclerosis
Rank Series r Description
54 GSE4595 −0.66 Motor cortex in sporadic amyotrophic
lateral sclerosiswith profiles corresponding to AD and Huntington’s
diseases (HD), see Table 3 and the two regression plots
in Figure 2C and D. When the PD profile is queried
against the rodent subset of SPIEDw we find that there
is a significant correlation with rodent models of neuro-
degeneration, see Table 4, and in particular a mouse
model of PD based on the administration of MPTP
(GEO accession GSE7707). This is in contrast to the AD
Figure 2 The regression plots for the PD query profile against high scoring PD, AD and HD expression studies in SPIEDw. The
regression plots are shown for high scoring PD expression profiles derived from post-mortem brain samples from two independent publications.
In A the PD query is plotted against a PD profile from the prefrontal cortex [20] and in B against a PD profile from the substantia nigra [21]. The
PD query also scores highly against other neurodegenaration disease profiles and two example regression plots are shown in C, for an AD profile
from the superior frontal gyrus [22], and D, a HD profile from the caudate nucleus [23].
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correlation with animal models of the disease (GW
unpublished observation). Again to get a better idea of the
overlap of the query profile with the rodent model profiles
we generated statistically filtered profiles for the various
conditions and generated regression scores. These are
shown in Table 4. Interestingly, the PD correlation with
the MPTP model only holds up in the striatum as
opposed to the midbrain or frontal cortex. Also, a signifi-
cant correlation emerges with late stage profiles of the
spinal chord injury model and the SOD1(G93A) model
of Amyotropic lateral sclerosis (ALS) (GEO accession
GSE18597), a similar result to previously published AD
query results [14]. The expression profiles used in the
regression analyses together with the PD query profile are
given in the Additional file 1.
Discussion and conclusions
The motivation behind SPIEDw is to facilitate the simple
quantitative comparison of biological states throughtheir underlying gene transcription profiles. In compari-
son to the previously published SPIED, the new database
has three notable improvements. Firstly, an enhanced
search algorithm has enabled queries to be performed in
‘real time’ on the web. Secondly, the number of expres-
sion samples comprising the database has been doubled,
now covering Illumina and Agilent as well as Affymetrix
platform technologies. Lastly, an abridged dataset com-
prising the most regulated genes has been included for a
speedier search and for gene set enrichment analysis.
The tool is simple to use, with queries consisting only of
gene names and expression changes. The output is
straightforward to interpret, giving direct links to the
deposited data for the high scoring SPIEDw entries. It
is hoped that this will open up gene expression data
mining to the wider research community. At present
SPIEDw consists of human and rodent arrays, where
there is a great deal of homology and mostly unambi-
guous gene assignment. However, there have been exten-
sive gene expression studies in more distant species,
Table 3 The PD query correlates with the expression
profiles of rodent models of neurodegeneration
Amyotrophic lateral sclerosis (ALS) model
Rank Series r Description
12 GSE18597 0.6 Mutant SOD1(G93A) transgenic mice
Ischemia
Rank Series r Description
44 GSE23163 0.56 Ischemic/reperfusion injury in an in vivo
mouse model
49 GSE23162 0.55 Ischemic/reperfusion injury in an in vivo
Gpx1 −/− transgenic mouse model
92 GSE28201 0.44 Ischemic Mouse Brain Transcriptome
93 GSE33725 0.44 Effect of erythropoietin on cerebral ischemia
in rat
Parkinson’s model
Rank Series r Description
55 GSE7707 −0.49 Mouse MPTP model of Parkinson’s disease
Spinal chord injury
Rank Series r Description
98 GSE5296 0.42 Spinal Cord Injury Murine Model
Other
Rank Series r Description
13 GSE18356 −0.61 Rat model of neonatal HI encephalopathy +/−
antioxidant
19 GSE24131 0.58 Hypoxia effect on mouse neural stem cells
41 GSE14802 0.52 Smith-Magenis and Potocki-Lupski syndrome
mouse model
54 GSE30577 −0.49 Brain and Spinal cord following Lethal
CVS-11 Infection in Mice
87 GSE25250 −0.44 Cerebellum from mice exposed to chronic
low-level chlorpyrifos oxon
88 GSE12196 0.53 Rat exposure to RDX
Table 4 The regression scores for the PD query profile
against mouse models of neurodegeneration
MPTP mouse PD model
Brain region r N
Striatum 0.39 56
Midbrain 0.08 32
Frontal cortex −0.19 31
SOD1 (G93A) mouse ALS model
stage (days) r N
28-40 0.21 63
112-126 0.48 104
Mouse spinal chord injury
stage r N
24 h 0.33 57
28 days 0.57 65
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direction with appropriate gene lists.Methods
Gene expression sample files were downloaded from
NCBI GEO (www.ncbi.nlm.nih.gov/geo/) covering human,
mouse and rat species on multiple platforms based on
Affymetrix, Illumina and Agilent technologies. In particu-
lar the platforms are: Affymetrix {GPL570, GPL96, GPL
6244, GPL571, GPL1261, GPL81, GPL6246, GPL85, GPL1
355}; Illumina {GPL6947, GPL6104, GPL6883, GPL6102,
GPL10558, GPL6884, GPL6887, GPL6885, GPL6105}; Agi
lent {GPL4133, GPL6480, GPL1708, GPL4134, GPL7202,
GPL4135, GPL7294, GPL2877, GPL890}. As in the ori-
ginal version of SPIED, the array probe sets are mapped
onto HGNC human genes. Each sample entry of SPIEDw
consists of a list of genes ranked according to relative
expression level in the given series to which the sample
belongs. In addition an abridged database with individual
sample entries corresponding to the top 500 most up/
down regulated genes has been generated for fast que-
rying. Here the top 500 up/down regulated genes are
assigned only up/down status and query correlations are
based on a Fisher exact test, see below. This database can
also be queried for gene set enrichment analysis. Drug
treatment data was downloaded from the Broad connec-
tivity map site and here multiple drug instances were
combined to obtain average response profiles and the
SPIEDw entries for these consist of the ranked list of
significantly affected genes (p < 0.05 by Student’s t-test)
according to fold magnitude.
For full and drugs set searches query profiles are scored
according to the significance of the Pearson’s correlation.







  , where
r is the Pearson’s correlation coefficient and N is the num-
ber of genes in the given correlation. To enable the user
to make an assessment of the significance of the output, r,
s and N are provided for each sample. The abridged data-
base search is based on a Fisher exact test, where the given
distribution of query genes in each database entry is com-
pared to a random distribution and scored accordingly.
Here, the separate enrichment scores for the up and down
regulated genes are combined for the ranking score.
Therefore a meaningful significance score will result from
queries without fold change information. That is, the
abridged database search can be used to look for enrich-
ment of gene sets. In this case the query consists of a gene
list with folds set to unity, see Additional file 2 for details.
To speed up database querying the data has been com-
pressed into a base 150 format. Here the overwhelming
majority of gene numbers are represented by no more
than two indices, corresponding to ASCII characters.
This results in a compression ratio of 59%. Data is read
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verting the read buffers to integers is as fast for the base
150 data as for the uncompressed data.
Availability of SPIED
SPIEDw is available at www.spied.org.uk. Current ver-
sion is 2.0 and new builds will become available in due
course, incorporating more recent expression data.
Additional files
Additional file 1: Expression profile details for queries used in
Results analysis together with corresponding correlating profiles
from SPIEDw. Excel spread sheet. with gene names, fold changes and
p-values for transcripts with significantly altered expression levels for the
example PD query and correlating profiles from PD, AD, HD human
samples. Correlating profiles form a mouse MPTP model of PD together
with a mouse SOD1(G93A) model of ALS and a mouse model of spinal
chord injury are also given.
Additional file 2: Example of SPIEDw with gene set query. A worked
example with a query consisting of a gene set. Querying the abridged
database (‘FAST’ mode query) enables the user to discover SPIEDw
response profiles with significantly enriched query gene sets.
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